Health & Fitness
Thu, August 5, 2010Wed, August 4, 2010Tue, August 3, 2010Mon, August 2, 2010Fri, July 30, 2010Thu, July 29, 2010Wed, July 28, 2010Tue, July 27, 2010Mon, July 26, 2010Fri, July 23, 2010Thu, July 22, 2010Wed, July 21, 2010Tue, July 20, 2010Mon, July 19, 2010Sun, July 18, 2010Sat, July 17, 2010Fri, July 16, 2010Thu, July 15, 2010Obagi Medical Products to Report Second Quarter 2010 Financial Results and Host a Conference Call on August 5
Published in Health and Fitness on Tuesday, July 27th 2010 at 10:15 GMT by Market Wire
LONG BEACH, Calif.--([ BUSINESS WIRE ])--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced that its second quarter 2010 financial results will be released after the market close on Thursday, August 5, and will be followed by an investor conference call on the same day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Investors interested in participating in the live call can dial 877-407-9039 from the U.S. International callers can dial 201-689-8470. A telephone replay will be available approximately two hours after the call concludes through Thursday, August 19, by dialing 877-660-6853 from the U.S., or 201-612-7415 for international callers, and entering account number 3055 and conference ID 354405.
There also will be a simultaneous webcast available on the Investor Relations section of the Company's web site at [ www.obagi.com ]. For those unable to participate during the live broadcast, the webcast will be archived for 30 days.
About Obagi Medical Products, Inc.
Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeuticsa" technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier to treat the most common and visible skin conditions in adults including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. The history of Obagi Medical's skin care product introductions is as follows: Obagi Nu-Derm®, 1988; Obagi-C® Rx (the first prescription-strength vitamin C and hydroquinone system), 2004; Obagi® Professional-C (a line of highly stable vitamin C serums), 2005; Obagi Condition & Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm® eye treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, 2007; Obagi ELASTIderm® D©colletage System, 2008; the Obagi Rosaclear® System for rosacea, 2009; and Refissaa" Tretinoin Emollient Cream, 0.05%, 2009. Visit [ www.obagi.com ] for more information.
